Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
暂无分享,去创建一个
V. Mazzaferro | J. Llovet | N. Bardeesy | D. Sia | Josep M Llovet | Nabeel Bardeesy | Vincenzo Mazzaferro | Daniela Sia | Agrin Moeini | A. Moeini | Agrin Moeini
[1] T. Roskams,et al. Hepatic Progenitor Cells: An Update. , 2017, Gastroenterology clinics of North America.
[2] P. Jänne,et al. Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. , 2015, Cancer research.
[3] J. Llovet,et al. YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. , 2015, Cell reports.
[4] S. Barry,et al. WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited. , 2015, The Journal of clinical investigation.
[5] Grégoire Pau,et al. Differential effects of targeting Notch receptors in a mouse model of liver cancer , 2015, Hepatology.
[6] Keith A. Boroevich,et al. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity , 2015, Nature Communications.
[7] E. Schadt,et al. Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma , 2015, Nature Communications.
[8] G. Mills,et al. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications , 2014, PloS one.
[9] Nansheng Chen,et al. Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.
[10] M. Grompe,et al. Bipotential adult liver progenitors are derived from chronically injured mature hepatocytes. , 2014, Cell stem cell.
[11] K. Ross,et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer , 2014, Nature.
[12] B. Njei. Changing pattern of epidemiology in intrahepatic cholangiocarcinoma , 2014, Hepatology.
[13] F. Couch,et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. , 2014, Human pathology.
[14] A. Ejaz,et al. Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets , 2014, Annals of Surgical Oncology.
[15] T. Pawlik,et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. , 2014, Journal of hepatology.
[16] Lei-bo Xu,et al. Clinicopathological significance of aberrant Notch receptors in intrahepatic cholangiocarcinoma. , 2014, International journal of clinical and experimental pathology.
[17] L. Wood,et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups , 2014, Oncotarget.
[18] Y. Totoki,et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma , 2014, Hepatology.
[19] David M. Jones,et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. , 2014, The oncologist.
[20] A. Iafrate,et al. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] G. Riggins,et al. Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells , 2014, Tumor Biology.
[22] S. Forbes,et al. Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma. , 2014, Cancer research.
[23] Eric W. Klee,et al. Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma , 2014, PLoS genetics.
[24] Christopher R. Schmidt,et al. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway , 2014, Hepatology.
[25] G. Gores,et al. Pathogenesis, diagnosis, and management of cholangiocarcinoma. , 2013, Gastroenterology.
[26] Swe Swe Myint,et al. Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers , 2013, Nature Genetics.
[27] T. Pawlik,et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas , 2013, Nature Genetics.
[28] R. Plentz,et al. Activation of Notch Signaling Is Required for Cholangiocarcinoma Progression and Is Enhanced by Inactivation of p53 In Vivo , 2013, PloS one.
[29] S. Lowe,et al. Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target , 2013, Proceedings of the National Academy of Sciences.
[30] J. Llovet,et al. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies , 2013, Oncogene.
[31] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[32] Nickolay A. Khazanov,et al. Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.
[33] D. Häussinger,et al. Hepatic stem cell niches. , 2013, The Journal of clinical investigation.
[34] Rameen Beroukhim,et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. , 2013, Gastroenterology.
[35] S. Hattori,et al. Clinicopathologic Analysis of Combined Hepatocellular-Cholangiocarcinoma According to the Latest WHO Classification , 2013, The American journal of surgical pathology.
[36] R. Wells,et al. Robust cellular reprogramming occurs spontaneously during liver regeneration. , 2013, Genes & development.
[37] Derek Y. Chiang,et al. Mutations in Isocitrate Dehydrogenase 1 and 2 Occur Frequently in Intrahepatic Cholangiocarcinomas and Share Hypermethylation Targets with Glioblastomas , 2012, Oncogene.
[38] M. Manns,et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. , 2013, Cancer cell.
[39] J. Llovet,et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. , 2012, Gastroenterology.
[40] Hyun Goo Woo,et al. Transcriptomic profiling reveals hepatic stem‐like gene signatures and interplay of miR‐200c and epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma , 2012, Hepatology.
[41] Sayaka Sekiya,et al. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. , 2012, The Journal of clinical investigation.
[42] H. Thomas,et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update , 2012, Gut.
[43] T. Therneau,et al. Biliary Tract Cancers in Olmsted County, Minnesota, 1976–2008 , 2012, The American Journal of Gastroenterology.
[44] G. Gores,et al. Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.
[45] Bin Tean Teh,et al. Exome sequencing of liver fluke–associated cholangiocarcinoma , 2012, Nature Genetics.
[46] Itzhak Avital,et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. , 2012, Gastroenterology.
[47] H. Thomas,et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? , 2012, Journal of hepatology.
[48] G. Gores,et al. Clinical diagnosis and staging of cholangiocarcinoma , 2011, Nature Reviews Gastroenterology &Hepatology.
[49] M. Choti,et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] B. Graubard,et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database , 2011, Hepatology.
[51] H. El‐Serag,et al. Risk factors for cholangiocarcinoma , 2011, Hepatology.
[52] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[53] Jian Yu,et al. Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma , 2011, PloS one.
[54] T. Pawlik,et al. Intrahepatic cholangiocarcinoma: An international, multi-institutional analysis of prognostic factors and lymph node assessment. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] Lequn Li,et al. Evaluation of Risk Factors and Clinicopathologic Features for Intrahepatic Cholangiocarcinoma in Southern China: A Possible Role of Hepatitis B Virus , 2011, Annals of Surgical Oncology.
[56] D. Calvisi,et al. The Hippo–Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis , 2010, Proceedings of the National Academy of Sciences.
[57] Jung-Hwan Yoon,et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. , 2010, Cancer research.
[58] D. Cunningham,et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.
[59] F. Lemaigre,et al. Organogenesis and development of the liver. , 2010, Developmental cell.
[60] Ju-Seog Lee,et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver , 2010, Proceedings of the National Academy of Sciences.
[61] Derek Y. Chiang,et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.
[62] X. Wang,et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.
[63] Derek Y. Chiang,et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.
[64] S. Yun,et al. Hepatitis B Virus Infection and Intrahepatic Cholangiocarcinoma in Korea: A Case-Control Study , 2008, The American Journal of Gastroenterology.
[65] S. Taylor-Robinson,et al. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[66] M. Matsuda,et al. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin , 2007, Hepatology.
[67] B. Graubard,et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[68] Steven C Cunningham,et al. Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution , 2007, Annals of surgery.
[69] Manal M. Hassan,et al. Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based Case–Control Study , 2007, The American Journal of Gastroenterology.
[70] W. Jeon,et al. Gene amplification and protein overexpression of HER-2/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node-positive patients. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[71] R. Schmid,et al. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials , 2007, British Journal of Cancer.
[72] Yusuke Nakamura,et al. Comparison of gene expression profiles between Opisthorchis viverrini and non‐Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma , 2006, Hepatology.
[73] T. Roskams. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma , 2006, Oncogene.
[74] S. Thorgeirsson,et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.
[75] T. Venesio,et al. Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma , 2006, Clinical Cancer Research.
[76] G. Gores,et al. Inducible nitric oxide synthase up-regulates Notch-1 in mouse cholangiocytes: implications for carcinogenesis. , 2005, Gastroenterology.
[77] S. Kubo,et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma , 2004, Cancer Science.
[78] F. Callea,et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case–control study in Italy , 2001, Cancer Causes & Control.
[79] T. Patel,et al. Worldwide trends in mortality from biliary tract malignancies , 2002, BMC Cancer.
[80] T. Patel. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.
[81] H. Thomas,et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998 , 2001, Gut.